Shares in Aerie Pharmaceuticals (NSDQ:AERI) held steady today after the eye-drug maker missed earnings expectations on Wall Street with its fourth-quarter and full-year financial results.
The Durham, N.C.-based company posted a net loss of -$58.5 million, or -$1.60 per share, for the 3 months ended Dec.31.
Get the full story at our sister site, Drug Delivery Business News.
The post Aerie misses Q4 earnings estimates by 11¢ appeared first on MassDevice.